Analytical Data
-
Gene name
MYCL2
- Application
-
Alternative Names
MYCLP1; MYCL1P1; MYCL2; Putative myc-like protein MYCLP1; Protein L-Myc-2; V-myc myelocytomatosis viral oncogene homolog pseudogene 1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P12525
-
Expression Region
1-358 aa
-
AA Sequence
MDRDSYHHYF YDYDGGEDFY RSTTPSEDIW KKFELVPPPW DLGPAAGNPA LSFGLLEPWP VGCAGDETES QDYWKAWDAN YASLIRRDCM WSGFSTQEPL ERAVSDLLAV GAPSGYSPKE FATPDYTPEL EAGNLAPIFP CLLGEPKIQA CSRSESPSDS EGEEIDVTVK KRQSLSTRKP VIIAVRADLL DPRMNLFHIS IHQQQHNYAA PFPPESCFQE GAPKRMPPKE ALEREAPGGK DDKEDEEIVS LPPVESEAAQ SCQPKPIHYD TENWTKKKYH SYLERKRRND QRSRFLALRD EVPALASCSR VSKVMILVKA TEYLHELAEA EERMATEKRQ LECQRRQLQK RIEYLSSY
-
Molecular Weight
40.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MYCL2, a member of the MYC family of transcription factors, plays a pivotal role in cell growth, differentiation, and apoptosis. Research has shown that MYCL2 is overexpressed in various cancers, making it a potential biomarker and therapeutic target. Its significance in oncogenic pathways has prompted scientists to investigate its functional mechanisms, including its role in gene regulation and interaction with other signaling pathways. Recombinant MYCL2 protein studies aim to elucidate the protein's structure-function relationship, provide insights into its role in tumorigenesis, and explore its potential in cancer therapy. The production of recombinant MYCL2 proteins allows researchers to perform detailed biochemical assays, structural analysis, and functional studies. These investigations can lead to a better understanding of MYCL2's contribution to malignancies and aid in the development of targeted therapies to inhibit its activity in cancer cells. The ongoing research into MYCL2 not only enhances our knowledge of cancer biology but also opens avenues for innovative treatment strategies aimed at improving patient outcomes.











